Type 1 Diabetes Clinical Trials: Immunotherapy Breakthroughs Reshaping Prevention in

What Are the Latest Type 1 Diabetes Clinical Trials in 2026?

The type 1 diabetes clinical trial landscape has expanded significantly since the FDA approved teplizumab (marketed as Tzield) in November 2022 — the first therapy shown to delay the onset of Stage 3 T1D in at-risk individuals aged 8 and older. That approval, based on data from the TrialNet TN-10 study, demonstrated a median delay of approximately two years in disease progression. Subsequent follow-up data has suggested even longer benefits for many participants, energizing the field to pursue additional immunomodulatory strategies.

Breakthrough T1D Canada (formerly JDRF Canada) has highlighted several active clinical programs exploring complementary mechanisms of action. These include trials investigating low-dose anti-thymocyte globulin (ATG), combination approaches pairing immunotherapy with metabolic support agents, and antigen-specific tolerization strategies designed to retrain the immune system to stop attacking insulin-producing beta cells. The TrialNet network, an international consortium of clinical trial centers, continues to screen relatives of people with T1D for autoantibodies, identifying at-risk individuals who may benefit from preventive interventions.

How Does Immunotherapy Prevent Type 1 Diabetes Progression?

Type 1 diabetes is an autoimmune condition in which the body's T cells mistakenly attack and destroy the insulin-producing beta cells in the pancreatic islets of Langerhans. By the time clinical symptoms appear — typically in children and young adults — an estimated 80–90% of beta cell function has already been lost. Immunotherapy interventions aim to interrupt this destructive process at earlier stages, when meaningful beta cell mass can still be preserved.

Teplizumab, an anti-CD3 monoclonal antibody, works by modifying the behavior of autoreactive T cells, essentially dampening the immune attack on beta cells. Researchers are now exploring whether combining such approaches with agents that support beta cell regeneration or survival could extend benefits further. According to the International Diabetes Federation, over 1.2 million children and adolescents live with T1D globally, making early intervention strategies a critical public health priority. The goal is shifting from managing T1D after diagnosis to preventing or substantially delaying its onset in genetically susceptible individuals identified through autoantibody screening programs.

What Does This Mean for Patients and Families at Risk?

For families with a history of type 1 diabetes, the expanding clinical trial ecosystem represents a meaningful shift in care. First-degree relatives of people with T1D have approximately a 5% lifetime risk of developing the condition — roughly 15 times higher than the general population. Organizations like Breakthrough T1D and the TrialNet Prevention Network now offer free autoantibody screening to identify at-risk individuals before symptoms develop, enabling enrollment in prevention trials during the critical window when intervention is most likely to succeed.

Clinicians emphasize that while no cure yet exists, the ability to delay T1D onset by even a few years can have profound impacts, particularly for young children. Delaying diagnosis allows for greater physical and cognitive maturity before the demands of insulin management begin. As more immunotherapy candidates advance through clinical trials, researchers anticipate that combination and sequential treatment strategies may eventually extend disease-free intervals far beyond what any single agent achieves alone.